Quantcast
 
New ETF Book by Larry Connors - Click here to read more


 

Generic plan B pregnancy prevention approved for teens

Tue. July 07, 2009; Posted: 08:24 AM
Stocks RSS

Look up the PowerRating of DRMD and see how it has performed over the past week as well as the current proprietary PowerRating.

KARACHI, Jul 06, 2009 (Asia Pulse Data Source via COMTEX) -- DRMD | Quote | Chart | News | PowerRating -- A generic version of the morning-after-pill known as Plan B has received Food and Drug Administration (FDA) approval for prescription use by women aged 17 and under. For the present the pill is available only to those under 17, but it will be available for other ages after August 24 when the exclusive market rights of Duramed Pharmaceuticals, Inc. manufacturers of the original Plan B expires. The new generic version is manufactured by Watson Pharmaceuticals of Corona, California. They call their version Next Choice.

The original pill was approved in 1999 for women of all ages and was dispensed by prescription only. In 2006 non-prescription use was approved for women ages 18 and older, but younger women could obtain the pill only by prescription. The 18-year-old age limit had been imposed by the Bush Administration. In April 2009 a federal court decided that this age limit was politics and not science and the FDA was directed to make Plan B available to those 17 years and younger without a prescription.

This did not mean that 17 year olds had immediate access to the drug, only that the manufacturer could make an application for over-the-counter sales to those 17 and younger. To date there is no information that such an application has been filed. If the drug was approved for OTC sales it would not be on open shelves, but would be available through the pharmacy.

If taken within 72 hours of intercourse the generic version (levonorgestrel 0.75 mg) reduces the risk of pregnancy. According to scientists it does not terminate a pregnancy. The drug is a contraceptive only, and it will not protect against sexually transmitted diseases, including HIV.

The morning-after-pill has generated controversy since it was first available, and the current decision to make it available to teenagers without prescription has disturbed conservatives. They believe that it will degrade the family by allowing teenagers access to contraceptives without their parents approval. Some pro-life advocates consider the concept of the pill not as emergency contraception but a form of abortion.

In MedPage Today, Cecile Richards, president of Planned Parenthood Federation of America, called the announcement a strong statement to American women that their health comes before politics. This decision is commonsense policy that will help reduce the number of unintended pregnancies and protect the health and safety of all women.

For full details for DRMD click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.